Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v9-FR | Version v1-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2021-12-15 | 2021-04-05 |
| Drug Identification Number | 02139502 | 02139502 |
| Brand name | VASOPRESSIN INJECTION | VASOPRESSIN INJECTION |
| Common or Proper name | Vasopressin Injection 20 units/mL MD Vial 1 mL | Vasopressin Injection 20 units/mL MD Vial 1 mL |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | VASOPRESSIN | VASOPRESSIN |
| Strength(s) | 20UNIT | 20UNIT |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAMUSCULAR SUBCUTANEOUS INTRAMUSCULAR SUBCUTANEOUS | INTRAMUSCULAR SUBCUTANEOUS INTRAMUSCULAR SUBCUTANEOUS |
| Packaging size | 1 mL | 1 mL |
| ATC code | H01BA | H01BA |
| ATC description | POSTERIOR PITUITARY LOBE HORMONES | POSTERIOR PITUITARY LOBE HORMONES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2021-04-05 | 2021-04-05 |
| Estimated end date | Unknown | 2021-04-30 |
| Actual end date | 2021-12-09 | 2021-04-30 |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada Ltd. would like to advise that our Vasopressin Injection 20 units/mL MD Vial 1 mL allocation will be adjusted to 100%. Contract customers will be allocated 100% of their historical average monthly volumes, effective immediately until April 30, 2021. (Product was initially on 200% allocation) | |
| Health Canada comments |